Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis.
Amogh Rajeev NadkarniSwapna C VijayakumaranSudeep GuptaJigeeshu Vasishtha DivatiaPublished in: JCO global oncology (2021)
Most studies were reported before the results of trials suggesting the benefit of dexamethasone and tocilizumab, potentially overestimating mortality. The observed mortality of 60% in cancer patients with COVID-19 admitted to the ICU is not prohibitively high, and admission to the ICU should be considered for selected patients (registered with PROSPERO, CRD42020207209).
Keyphrases
- intensive care unit
- cardiovascular events
- papillary thyroid
- end stage renal disease
- mechanical ventilation
- coronavirus disease
- squamous cell
- rheumatoid arthritis
- ejection fraction
- risk factors
- sars cov
- newly diagnosed
- emergency department
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cardiovascular disease
- type diabetes
- systemic lupus erythematosus
- young adults
- patient reported outcomes
- extracorporeal membrane oxygenation
- case control